AHA: AstraZeneca's Brilinta linked to less bleeding solo than as an aspirin add-on

AstraZeneca
Acute coronary syndrome patients taking AstraZeneca's Brilinta alone suffered fewer bleeding episodes than those taking the drug alongside aspirin, so-called dual platelet therapy. (AstraZeneca)

PHILADELPHIA—AstraZeneca's longtime clot-buster Brilinta has seen some of its shine wear off as other drugs––not the least of which is SGLT2 star Farxiga––have charted a new course. But the British drugmaker still has hopes for its old stalwart, and aspirin-beating bleeding data in acute coronary syndrome (ACS) could help. 

Solo Brilinta beat out a Brilinta-aspirin combo on the safety side, reducing clinically relevant bleeding while matching up on efficacy. The results came after 12 months in ACS patients who underwent a percutaneous coronary intervention with at least one stent.

Those data were presented Saturday at the American Heart Association's Scientific Sessions as part of a subgroup analysis from Brilinta's phase 3 Twilight trial. On top of beating out dual-platelet therapy in reduced bleeding, solo Brilinta stood up to the Brilinta-aspirin combo in adverse CV events, including all-cause death, heart attacks and stroke. 

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

The subanalysis included 64% of the Twilight trial population. Following a three-month open-label period treating patients with Brilinta and aspirin, 4,614 patients free of ischemic events and bleeding were continued on either solo Brilinta or the Brilinta-aspirin combo. 

Patients treated with solo Brilinta posted a 53% relative risk reduction in types 2, 3 and 5 bleeding after one year, according to the Bleeding Academic Research Consortium ratings. Specifically in types 3 and 5, Brilinta alone posted a 64% relative risk reduction over the dual therapy. 

Naeem Khan, AstraZeneca's medical VP of cardiovascular and metabolic disease, said the newest data challenged a more than 20-year-old standard of dual-platelet therapy in treating ACS. 

"This is a paradigm shift in thinking about dual therapy," Khan said. 

RELATED: AstraZeneca's Brilinta wins in diabetic artery disease patients

The subanalysis helps builds Brilinta's case for ACS patients after the completion of its Twilight trial studying Brilinta as an add-on to aspirin in treating the syndrome. 

Back in February, Brilinta added to aspirin slashed the combined risk of heart attack, stroke and cardiovascular death in patients with Type 2 diabetes with coronary artery disease who hadn’t suffered a prior heart attack or stroke. The combination topped aspirin alone in the 19,000-plus patient trial, a phase 3 study dubbed Themis.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.